Brittany Miller
Family · Ville Platte, LANPI 1255798344
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $148,976 of the $157,804 with a category attached, or 94.4%. Galderma Laboratories, L.p. accounts for 99.7% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2022 at $47,598 and has fallen 66.7% since, to $15,848 in 2025. Among family clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 156 payments — averaging $1011.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Galderma Laboratories, L.p.$157K
- Revance Therapeutics, Inc.$154
- Coloplast$101
- AbbVie$74
- Mayne Pharma Commercial LLC$24
- Lilly USA, LLC$22
- plus $79 from 5 others
What the payments were for
- Speaking & faculty fees$148,97694%
- Travel & lodging$7,9535%
- Food & beverage$8761%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Galderma Laboratories, L.p. | 141 | $157,350 |
| Revance Therapeutics, Inc. | 2 | $154 |
| Coloplast | 1 | $101 |
| AbbVie | 4 | $74 |
| Mayne Pharma Commercial LLC | 2 | $24 |
| Lilly USA, LLC | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Merck | 1 | $13 |
| GSK | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TITAN$101
How this compares
$157,804 in reported general payments places this provider in the 95th percentile of 3,610 family providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 42 | $38,410 |
| JardianceEmpagliflozin | 24 | $20,082 |
| RybelsusSemaglutide | 11 | $12,283 |
| LinzessLinaclotide | 16 | $8,201 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $4,531 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 85 | $2,524 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $1,467 |
| Sucralfate | 15 | $1,302 |
| Gabapentin | 79 | $772 |
| Atorvastatin Calcium | 142 | $607 |
| Pioglitazone Hcl | 54 | $579 |
| Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide | 93 | $366 |
| Amlodipine Besylate | 160 | $334 |
| Pantoprazole Sodium | 62 | $329 |
| Omeprazole | 80 | $328 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $74 | $8,20116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,610 family providers in Louisiana.
Other family in Ville Platte
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
- Tiffany RoeShreveport$97K
- Ghenet GhebretatiosBaton Rouge$91K
- Kimberly RaoAlexandria$84K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.